How FOXA1 affects immune responses in prostate cancer
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
This study is looking at how a protein called FOXA1 affects the immune system in prostate cancer, especially in cases where standard treatments aren't working, to find new ways to help the body fight the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10892845 on NIH RePORTER |
What this research studies
This research investigates the role of FOXA1, a transcription factor, in regulating immune responses and cytokine signaling in prostate cancer. It focuses on understanding how FOXA1 influences the tumor-immune microenvironment, particularly in cases of castration-resistant prostate cancer (CRPC), where traditional therapies often fail. By examining the interactions between FOXA1 and immune cells, the study aims to uncover mechanisms that lead to immunosuppression in tumors, potentially paving the way for new therapeutic strategies. The research employs various molecular biology techniques to analyze tumor samples and immune cell behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, especially those who have developed resistance to standard androgen deprivation therapies.
Not a fit: Patients with early-stage prostate cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for prostate cancer patients, particularly those with castration-resistant forms of the disease.
How similar studies have performed: Previous studies have shown promise in targeting immune responses in other cancers, suggesting that this approach could yield valuable insights for prostate cancer as well.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Yu, Jindan — Emory University
- Study coordinator: Yu, Jindan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.